Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.51 |
| ▸ | FAP | Q12884 | 5/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.51 |
| ▸ | PITRM1 | Q5JRX3 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8288240 | 0.90 | DPP4 (0.55) | DPP4DPP9FAPDPP8DPP7 | |
| SCHEMBL13347239 | 0.87 | DPP4 (0.50) | DPP4DPP9FAPDPP8DPP7 | |
| SCHEMBL8288248 | 0.85 | MEN1 (0.48) | DPP4DPP9FAPDPP8DPP7 | |
| SCHEMBL13347235 | 0.84 | DPP4 (0.64) | DPP4DPP9FAPDPP8DPP7 | |
| SCHEMBL13452746 | 0.80 | POLB (0.41) | DPP4DPP9FAPDPP8DPP7 | |
| SCHEMBL8214183 | 0.80 | EPHX2 (0.41) | DPP4DPP9FAPDPP8DPP7 | |
| SCHEMBL8288245 | 0.80 | EPHX2 (0.39) | DPP4FAPEPHX2LMNAPREP | |
| SCHEMBL13347237 | 0.79 | DPP4 (0.50) | DPP4DPP9FAPDPP8DPP7 | |
| SCHEMBL13347238 | 0.79 | DPP4 (0.49) | DPP4DPP9FAPDPP8DPP7 | |
| SCHEMBL13347220 | 0.78 | EPHX2 (0.40) | DPP4DPP9FAPDPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415295-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20100120661-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | PHENOMIX CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7674913-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2010-03-09 | — | — | US | disclosed |
| US-20070185061-A1 | (2R)-1-{2-[(3R)-pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; Dipeptidyl peptidase IV (DPP-IV) inhibitors; diabetes, hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis | PHENOMIX CORPORATION | 2007-08-09 | — | — | US | disclosed |
| US-20070060547-A1 | (2R)-1-{2-[(3R)-pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; Dipeptidyl peptidase IV (DPP-IV) inhibitors; diabetes, hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis | PHENOMIX CORPORATION | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060547-A1 | (2R)-1-{2-[(3R)-pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; Dipeptidyl peptidase IV (DPP-IV) inhibitors; diabetes, hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis | DPP4, DPP7, DPP3 | DPP4 1/4885DPP9 6/4885FAP 269/4885 |
| US-20070185061-A1 | (2R)-1-{2-[(3R)-pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; Dipeptidyl peptidase IV (DPP-IV) inhibitors; diabetes, hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis | DPP4, DPP7, DPP3 | DPP4 1/4885DPP9 5/4885FAP 209/4885 |
| US-20100120661-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | DPP4, DPP7, DPP3 | DPP4 1/4885DPP9 7/4885FAP 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.